Friday, September 8, 2017

'Triple negative breast cancer' treatment studied

African scholarship student is working on potential cure for a subtype of cancer for blacks 

A Sierra Leonean student reportedly is developing an alternative breast cancer treatment for black women.

Sandra Musujusu
According to a recent story by Taryn Finley on the Huffpost website, the research of Sandra Musujusu, a student at the African University of Science and Technology in Abuja, Nigeria's capital, is focusing on "triple negative breast cancer, which is actually the aggressive subtype of breast cancer that is common with women from African ancestry."

The Huffpost piece references an article in the Nigerian Tribune that reported the research centering on "the development of biodegradable polymers for treatment of breast cancer."

A variety of African publications have been sanguine about Musujusu's research potentially leading to a cure.

She apparently is using macro molecular science as her basic tool.

Breast cancer, the Huffpost story indicated, "is the most commonly diagnosed caner among women around the world. In 2012, there were 1.7 million new cases worldwide, according to World Cancer Research Fund International."

An online article on the Rollingout website says that "about 1 in 8 U.S. women "will develop invasive breast cancer over the course of her lifetime, according to"

The National Cancer Institute has reported that approximately 1,211,690 black people have a history of cancer.

In the United States alone, the Huffpost story notes, "black women with breast cancer have the highest mortality rate than any other race, according to the Susan G. Women Foundation."

And the National Cancer Institute has said approximately 1,211,690 black people have a history of cancer.

Musujusu is a World Bank scholarship student.

More information about breast cancer and black women can be found in "Rollercoaster: How a man can survive his partner's breast cancer," a VitalityPress book I, Woody Weingarten, aimed at male caregivers.

No comments:

Post a Comment